Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/69918
Title: | Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial | Authors: | Michels, Sebastian Massutí, Bartomeu Schildhaus, Hans Ulrich Franklin, Jeremy Sebastian, Martin Felip, Enriqueta Grohé, Christian Rodriguez-Abreu, Delvys Abdulla, Diana S.Y. Bischoff, Helge Brandts, Christian Carcereny, Enric Corral, Jesús Dingemans, Anne Marie C. Pereira, Eva Fassunke, Jana Fischer, Rieke N. Gardizi, Masyar Heukamp, Lukas Insa, Amelia Kron, Anna Menon, Roopika Persigehl, Thorsten Reck, Martin Riedel, Richard Rothschild, Sacha I. Scheel, Andreas H. Scheffler, Matthias Schmalz, Petra Smit, Egbert F. Limburg, Meike Provencio, Mariano Karachaliou, Niki Merkelbach-Bruse, Sabine Hellmich, Martin Nogova, Lucia Büttner, Reinhard Rosell, Rafael Wolf, Jürgen |
UNESCO Clasification: | 320101 Oncología | Keywords: | Crizotinib Lung Cancer Ros1 Targeted Treatment Tp53 |
Issue Date: | 2019 | Journal: | Journal of Thoracic Oncology | Abstract: | Introduction: ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and East Asia. Here we present data on efficacy and safety of a prospective phase II trial evaluating crizotinib in European ROS1-positive patients (EUCROSS). Patients and Methods: The trial was a multicenter, single-arm phase II trial (Clinicaltrial.gov identifier: NCT02183870). Key eligibility criteria included patients who were 18 years of age or older with advanced/metastatic lung cancer and centrally confirmed ROS1-rearranged lung cancer (fluorescence-in situ hybridization). Treatment included 250 mg crizotinib twice daily. The primary endpoint was investigator-assessed objective response rate (ORR) (Response Evaluation Criteria in Solid Tumors, version 1.1). Key secondary endpoints were progression-free survival (PFS), overall survival, efficacy by independent radiologic review, safety, health-related quality of life, and molecular characterization of tumor tissue. Results: Thirty-four patients received treatment. Four patients were excluded from efficacy analysis. Investigator ORR was 70% (95% confidence interval [CI]: 51–85; 21 of 30 patients) and median PFS was 20.0 months (95% CI: 10.1–not reached). Two patients with ROS1 wild-type sequences assessed by DNA sequencing had progression as best response. CD74-ROS1-positive patients had a trend towards a higher ORR and longer median PFS. TP53-co-mutant patients had a significantly shorter median PFS than wild-type patients (7.0 months, 95% CI: 1.7–20.0 versus 24.1 months, 95% CI: 10.1–not reached; p = 0.022). Treatment-related adverse events were documented in 33 of 34 patients (97%). Conclusions: Crizotinib is highly effective and safe in patients with ROS1-rearranged lung cancer. ROS1-/TP53-co-aberrant patients had a significantly worse outcome compared to TP53 wild-type patients. | URI: | http://hdl.handle.net/10553/69918 | ISSN: | 1556-0864 | DOI: | 10.1016/j.jtho.2019.03.020 | Source: | Journal of Thoracic Oncology [ISSN 1556-0864],v. 14 (7), p. 1266-1276 |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
91
checked on Sep 29, 2024
WEB OF SCIENCETM
Citations
87
checked on Sep 29, 2024
Page view(s)
53
checked on Jan 20, 2024
Download(s)
118
checked on Jan 20, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.